The Eastern Cape Department of Health has announced plans to introduce the long-acting injectable HIV prevention drug, cabotegravir (CAB-LA), at selected public health facilities. The rollout is part of a national implementation plan following its approval by the South African Health Products Regulatory Authority (SAHPRA).
The injection, administered every two months, offers an alternative to daily oral pre-exposure prophylaxis (PrEP) for individuals at substantial risk of HIV infection. Initial phases will focus on making the treatment available at specific clinics, with plans for a wider expansion based on the initial program's outcomes and available resources.
Health officials emphasize that the injectable is intended to expand prevention choices, not replace existing methods like condoms or oral PrEP. The rollout includes healthcare worker training and community education to ensure informed uptake. This initiative aligns with South Africa's goal to reduce new HIV infections, a key part of the national strategic plan on HIV, TB, and STIs.
